Back to News
Market Impact: 0.25
PolyPid Targets 2027 D-PLEX100 Launch, Unveils Diabetic Foot Infection Program
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & OutlookCompany Fundamentals
PolyPid outlined plans at an investor day to expand its commercial and development strategy through 2030. The company is approaching a November 28, 2026 FDA action date for D-PLEX100, a surgical-site infection prevention product candidate.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
PYPD0.20
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Norwegian shares surge 13% on earnings beat, guidance raise
- Alphabet’s stock has worst day in over 20 years, dragging the S&P 500 to first loss in four days
- PC chip plunge wipes out a quarter of Intel’s value
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks